MabPlex's Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

Tuesday, January 15, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

MabPlex International, Ltd, a global Contract Development and Manufacturing Organization (CDMO) offering services in the development and manufacturing of biopharmaceuticals, announced that an Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for its customer's proprietary antibody drug.

YANTAI, China and SAN DIEGO, Jan. 15, 2019 /PRNewswire-PRWeb/ -- MabPlex International

Ltd, a leading and fully integrated Contract Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China and the United States by offering comprehensive (cell line) development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions for monoclonal antibody (mAb) and antibody-drug conjugate (ADC) therapeutics, announced today that an Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for its customer's proprietary antibody drug.

MabPlex was contracted to develop and manufacture the product from cell line development to IND filing in both the United States and China.

MabPlex provided fully integrated services from cell line development to final drug product including a complete CMC package in support of the United States IND submission. Additionally, the IND filing for the Chinese NMPA will be completed in the near future.

"This approval adds another milestone to our global repertoire of international IND submissions after the successful approval of an Australian IND last year," said Jianmin Fang, Ph.D, Chairman and Chief Executive Officer of MabPlex International, Ltd.

"MabPlex's high standards in development and cGMP quality management have been recognized by US, Australian and Chinese regulators demonstrating the strength of our global CDMO services," Fang added.

About MabPlex MabPlex, a leading and fully integrated Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform and comprehensive and integrated solutions to global biopharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing. With our state-of-the-art facilities and exemplary biologics development and manufacturing experience, MabPlex commits to being a valuable partner for our clients around the globe.

 

SOURCE MabPlex



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store